(Aug. 16, 2024) – On Aug. 9, the Food and Drug Administration
announced the approval of Neffy (epinephrine nasal spray) for the emergency treatment of allergic reactions (Type I), including those that are life-threatening (anaphylaxis), in adult and pediatric patients who weigh at least 30 kilograms. This is the first approval for epinephrine for the treatment anaphylaxis that is not administered by injection. It is anticipated that the epinephrine nasal spray may reduce barriers to the rapid treatment of anaphylaxis. The FDA granted Neffy
Fast Track designation for this application. The FDA granted the approval of Neffy to ARS Pharmaceuticals.
--
Karen Braman